Please login to the form below
pioglitazone
This page shows the latest pioglitazone news and features for those working in and with pharma, biotech and healthcare.
Another Alzheimer's bust as Merck & Co stops verubecestat study
Since the start of the year, Boehringer Ingelheim has stopped development of its PDE9a inhibitor BI 4093906, Takeda and Zinfandel abandoned efforts to repurpose diabetes drug pioglitazone for the disease, and
Latest news
-
Boehringer abandons PDE-targeted Alzheimer’s drug
Various other treatment approaches have also been tried and failed, including drugs targeting the serotonin pathway as well as diabetes medicine pioglitazone.
-
Takeda and Zinfandel abandon Alzheimer’s drug
Pioglitazone failed to show therapeutic improvements in late-stage testing. A phase III trial of pioglitazone in Alzheimer’s disease has been terminated by Takeda and partner Zinfandel Therapeutics after it ... Pioglitazone was being tested in people
-
NICE backs freer use of SGLT2 inhibitors for diabetes
The new guidance allows the drugs to be used first-line for people who cannot tolerate metformin, and in whom sulfonylureas or Takeda's Actos (pioglitazone) are not considered appropriate.
-
Takeda to pay $2.4bn to settle Actos cancer suits
Actos (pioglitazone) is licensed to help patients with type II diabetes reduce their sugar levels and has been on the market for more than 15 years.
-
US judge cuts billions from Takeda/Lilly Actos payment
8m. Rebecca Doherty, the US District Judge for the state of Louisiana, stopped short of overturning the verdict, which revolved around the risk of developing bladder cancer after taking Actos (pioglitazone), ... It was brought forward by plaintiff
More from news
Approximately 5 fully matching, plus 69 partially matching documents found.
Latest Intelligence
-
Interview: Trevor Smith, Takeda
Ulcer drug lansoprazole and prostate cancer treatment leuprorelin already faced generic competition and before the deal was completed Takeda's diabetes drug Actos (pioglitazone) lost exclusivity in January 2011.
-
Country report: The healthcare market in Japan
to its multi-billion dollar main product, the antidiabetic Actos (pioglitazone), in August. ... Takeda's patent on the blockbuster Actos (pioglitazone) for type 2 diabetes expired in January, but an agreement with generic drugmakers Ranbaxy, Watson and
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- bluebird bio’s beti-cel accepted for priority review by FDA
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
- Onyx Health Announces Two Top Appointments
- Omicron prompts global action
- Novo Nordisk growth takes a hit with China deal
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Six ways to improve diversity in clinical trials
- Innovation in a digital context is not about technology – it’s about people
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Novartis forms coronavirus alliance with life sciences companies
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
